BlueCross BlueShield of Tennessee Medical Policy Manual

Efgartigimod Alfa-fcab (Vyvgart®); Efgartigimod Alfa-fcab and Hyaluronidase-qvfc (Vyvgart®Hytrulo)



We develop Medical Policies to provide guidance to Members and Providers.  This Medical Policy relates only to the services or supplies described in it.  The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy.  For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed.  If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.




          I.    INDICATIONS


The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.


FDA-Approved Indication

Vyvgart and Vyvgart Hytrulo are indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.


All other indications are considered experimental/investigational and not medically necessary.





Submission of the following information is necessary to initiate the prior authorization review:

A.    For initial requests chart notes, medical records, or claims history documenting:

1.     Positive anti-acetylcholine receptor (AChR) antibody test

2.     Clinical classification of myasthenia gravis score

3.     MG activities of daily living score

4.     Use of an acetylcholinesterase (AChE) inhibitor, steroid, or non-steroidal immunosuppressive therapy (NSIST)

B.    For continuation requests: Chart notes or medical record documentation supporting positive clinical response.





  Generalized myasthenia gravis (gMG)

Authorization of 6 months may be granted for treatment of generalized myasthenia gravis (gMG) when all of the following criteria are met:

  1.    Anti-acetylcholine receptor (AChR) antibody positive

2.     Myasthenia Gravis Foundation of America (MGFA) clinical classification II to IV

3.     MG activities of daily living (MG-ADL) total score of 5 or more with at least 50% of the score due to non-ocular symptoms

4.     On a stable dose of at least one of the following:

a.     Acetylcholinesterase inhibitors (e.g., pyridostigmine)

b.     Steroids (at least 3 months of treatment)

c.     Nonsteroidal immunosuppressive therapy (NSIST) (at least 6 months of treatment) (e.g., azathioprine,  mycophenolate mofetil)





Authorization of 6 months may be granted for continued treatment in members requesting reauthorization when there is no evidence of unacceptable toxicity or disease progression while on the current regimen and member demonstrates a positive response to therapy (e.g., improvement in MG-ADL score, changes compared to baseline in Quantitative Myasthenia Gravis (QMG) total score).


BlueCross BlueShield of Tennessee’s Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.


For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).


1.     Vyvgart [package insert]. Boston, MA: Argenx US, Inc.; April 2022.

2.     Vyvgart Hytrulo [package insert]. Boston, MA: Argenx US. Inc.; June 2023.

3.     Sanders D, Wolfe G, Benatar M et al. International consensus guidance for management of myasthenia gravis. Neurology. 2021; 96 (3) 114-122.

4.     Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021. 20:526-536.




Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information.